These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 32334165)

  • 1. The Impact of the Pharmaceutical Care Management Model of Hepatitis C Medications on the Cost at Health Insurance Level.
    Almahdi FB; Hashim AH; Albaba EAM; Salih ON; Alkasam RJ; Mosli MH; Alsulaimani AF
    Value Health Reg Issues; 2020 May; 21():230-237. PubMed ID: 32334165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Pharmacy-Led Hepatitis C Direct-Acting Antiviral Utilization Management at a Veterans Affairs Medical Center.
    Yang S; Britt RB; Hashem MG; Brown JN
    J Manag Care Spec Pharm; 2017 Mar; 23(3):364-369. PubMed ID: 28230455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost burden of hepatitis C virus treatment in commercially insured patients.
    Lu CY; Ross-Degnan D; Zhang F; LeCates R; Lupton C; Sherman M; Wagner A
    Am J Manag Care; 2019 Dec; 25(12):e379-e387. PubMed ID: 31860232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing Access to Hepatitis C Virus Medications: A Program Model Using Patient Navigators and Specialty Pharmacy to Obtain Prior Authorization Approval.
    Vu TM; Toribio W; Riazi F; Ciprian G; Gibbs N; Giardina M; Camacho JA; Parrella K; Cambe J; Amory C; Chasan R; Sigel KM; Weiss JJ
    J Manag Care Spec Pharm; 2018 Apr; 24(4):329-333. PubMed ID: 29578854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system.
    Lam JO; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ; Marcus JL
    Int J STD AIDS; 2019 Jun; 30(7):689-695. PubMed ID: 31046611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local specialty pharmacy and specialty clinic collaboration assists access to hepatitis C direct-acting antivirals.
    Zhu J; Hazen RJ; Joyce C; Delpino A; Kirkham HS; Strickland CD; Markes-Wilson S; Kim T; Kang M; Rubin RA; Stein LL
    J Am Pharm Assoc (2003); 2018; 58(1):89-93.e2. PubMed ID: 29154019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of a pharmaceutical care program for patients with hepatitis C treated with new direct-action antivirals.
    Campos Fernández de Sevilla MÁ; Gallego Úbeda M; Heredia Benito M; García-Cabrera E; Monje García B; Tovar Pozo M; Delgado Téllez de Cepeda L; Iglesias-Peinado I
    Int J Clin Pharm; 2019 Apr; 41(2):488-495. PubMed ID: 31028599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a specialty hepatitis C virus telephone pharmacy service.
    Sabourin AA; Fisher-Grant KK; Saulles AR; Mohammad RA
    Am J Health Syst Pharm; 2021 May; 78(Supplement_2):S38-S45. PubMed ID: 33684928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of pharmacist care delivery models for hepatitis C clinics.
    Naidjate SS; Zullo AR; Dapaah-Afriyie R; Hersey ML; Marshall BDL; Winkler RM; Berard-Collins C
    Am J Health Syst Pharm; 2019 May; 76(10):646-653. PubMed ID: 30873537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.
    Maier MM; Zhou XH; Chapko M; Leipertz SL; Wang X; Beste LA
    Dig Dis Sci; 2018 Jun; 63(6):1454-1462. PubMed ID: 29453610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus infection and the role of a pharmaceutical care program.
    Chamorro-de-Vega E; Rodríguez-González CG; Giménez-Manzorro Á; Herranz A; Sanjurjo M
    Am J Health Syst Pharm; 2020 Mar; 77(6):479-486. PubMed ID: 31811290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system.
    Javanbakht M; Archer R; Klausner J
    PLoS One; 2020; 15(11):e0241615. PubMed ID: 33147293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015.
    Lu CY; Zhang F; Golonski N; Lupton C; Jeffrey P; Wagner AK
    Value Health; 2018 Jun; 21(6):692-697. PubMed ID: 29909874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct-acting antivirals: The GRUviC project.
    Chamorro-de-Vega E; Rodriguez-Gonzalez CG; Gimenez-Manzorro A; de Lorenzo-Pinto A; Iglesias-Peinado I; Herranz A; Sanjurjo M;
    Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28836363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Dillon JF
    BMJ Open; 2018 Dec; 8(12):e021443. PubMed ID: 30552244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of medication therapy management services for patients with cardiovascular disease in a self-insured employer health plan.
    Wittayanukorn S; Westrick SC; Hansen RA; Billor N; Braxton-Lloyd K; Fox BI; Garza KB
    J Manag Care Pharm; 2013 Jun; 19(5):385-95. PubMed ID: 23697476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system.
    Belperio PS; Backus LI; Ross D; Neuhauser MM; Mole LA
    J Manag Care Spec Pharm; 2014 Jun; 20(6):533-40. PubMed ID: 24856591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting.
    Overton K; Clegg J; Pekin F; Wood J; McGrath C; Lloyd A; Post JJ
    Int J Drug Policy; 2019 Oct; 72():123-128. PubMed ID: 30967329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era.
    Cacoub P; Vautier M; Desbois AC; Lafuma A; Saadoun D
    Liver Int; 2017 Dec; 37(12):1805-1813. PubMed ID: 28467688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.